Strikingly, Lamivudine was able to significantly reduce fat in an nhr-49/PPAR mutant background, suggesting the effects of this drug will be applicable as an anti-obesity intervention in people with Metabolic Syndrome. Here, PPARA is linked to obesity due to melanocortin 4 receptor deficiency.